Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward
Identifieur interne : 002823 ( Main/Curation ); précédent : 002822; suivant : 002824Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward
Auteurs : Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew J. Lees [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-05-15.
English descriptors
- KwdEn :
Abstract
A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use (“dopamine dysregulation syndrome”—DDS). DDS patients commonly identify aversive dysphoric “OFF” mood‐states as a primary motivation to compulsively use their drugs. We compared motoric, affective, non‐motor symptoms and incentive arousal after overnight medication withdrawal and after levodopa in DDS and control PD patients. Twenty DDS patients were matched to 20 control PD patients for age, gender, and disease duration and underwent a standard levodopa challenge. Somatic symptomatology, positive and negative affective states, drug effects, reward responsivity, motor disability, and dyskinesias were tested in the “OFF”‐state after overnight withdrawal of medications, and then after a challenge with a standard dose of levodopa, after a full “ON”‐state was achieved. In the “OFF”‐state, DDS patients reported lower positive affect, and more motor and non‐motor disability. In the “ON”‐state, DDS patients had higher expressions of drug “wanting,” reward responsivity, and dyskinesias. Positive and negative affect, non‐motor symptomatology, and motor disability were comparable. These findings suggest that affective, motivational, and motoric disturbances in PD are associated with the transition to compulsive drug use in individuals who inappropriately overuse their dopaminergic medication. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22898
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B90
Links to Exploration step
ISTEX:2981665EABC936B9FD65A2D7C00BDC8B290A17CDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward</title><author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Melbourne, Victoria, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Melbourne, Victoria</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Lawrence, Andrew D" sort="Lawrence, Andrew D" uniqKey="Lawrence A" first="Andrew D." last="Lawrence">Andrew D. Lawrence</name><affiliation wicri:level="1"><mods:affiliation>Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University, Cardiff, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University, Cardiff</wicri:regionArea></affiliation></author><author><name sortKey="Cresswell, Silke Appel" sort="Cresswell, Silke Appel" uniqKey="Cresswell S" first="Silke Appel" last="Cresswell">Silke Appel Cresswell</name><affiliation wicri:level="1"><mods:affiliation>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea></affiliation></author><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Donauspital/SMZ‐Ost, Vienna, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Donauspital/SMZ‐Ost, Vienna</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2981665EABC936B9FD65A2D7C00BDC8B290A17CD</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22898</idno><idno type="url">https://api.istex.fr/document/2981665EABC936B9FD65A2D7C00BDC8B290A17CD/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002B90</idno><idno type="wicri:Area/Main/Curation">002823</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward</title><author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Melbourne, Victoria, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Melbourne, Victoria</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Lawrence, Andrew D" sort="Lawrence, Andrew D" uniqKey="Lawrence A" first="Andrew D." last="Lawrence">Andrew D. Lawrence</name><affiliation wicri:level="1"><mods:affiliation>Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University, Cardiff, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University, Cardiff</wicri:regionArea></affiliation></author><author><name sortKey="Cresswell, Silke Appel" sort="Cresswell, Silke Appel" uniqKey="Cresswell S" first="Silke Appel" last="Cresswell">Silke Appel Cresswell</name><affiliation wicri:level="1"><mods:affiliation>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea></affiliation></author><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Donauspital/SMZ‐Ost, Vienna, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Donauspital/SMZ‐Ost, Vienna</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05-15">2010-05-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="867">867</biblScope><biblScope unit="page" to="876">876</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2981665EABC936B9FD65A2D7C00BDC8B290A17CD</idno><idno type="DOI">10.1002/mds.22898</idno><idno type="ArticleID">MDS22898</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>non‐motor</term><term>reward</term><term>withdrawal</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use (“dopamine dysregulation syndrome”—DDS). DDS patients commonly identify aversive dysphoric “OFF” mood‐states as a primary motivation to compulsively use their drugs. We compared motoric, affective, non‐motor symptoms and incentive arousal after overnight medication withdrawal and after levodopa in DDS and control PD patients. Twenty DDS patients were matched to 20 control PD patients for age, gender, and disease duration and underwent a standard levodopa challenge. Somatic symptomatology, positive and negative affective states, drug effects, reward responsivity, motor disability, and dyskinesias were tested in the “OFF”‐state after overnight withdrawal of medications, and then after a challenge with a standard dose of levodopa, after a full “ON”‐state was achieved. In the “OFF”‐state, DDS patients reported lower positive affect, and more motor and non‐motor disability. In the “ON”‐state, DDS patients had higher expressions of drug “wanting,” reward responsivity, and dyskinesias. Positive and negative affect, non‐motor symptomatology, and motor disability were comparable. These findings suggest that affective, motivational, and motoric disturbances in PD are associated with the transition to compulsive drug use in individuals who inappropriately overuse their dopaminergic medication. © 2010 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002823 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002823 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:2981665EABC936B9FD65A2D7C00BDC8B290A17CD
|texte= Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward
}}
| This area was generated with Dilib version V0.6.23. |  |